by Allison Sit
Healio wrote about two JDD studies on psoriasis treatments including one on the benefits of long-term ixekizumab. The study, “Benefits Over Five Years of Ixekizumab Treatment in Patients With Psoriasis Involving Challenging Body Areas,” was conducted by Alice B. Gottlieb, MD, PhD, and colleagues from around the world. Researchers conducted a post hoc analysis of 365 patients with moderate-to-severe plaque psoriasis treated with ixekizumab in the UNCOVER-3 trial. Researchers sought to determine whether there were any differences in clearance rates and clinical benefits in patients with and without baseline involvement in challenging body areas, such as the scalp, face, palmoplantar surfaces, nails, intertriginous areas and genitalia. Results showed that, in most cases, the clearance response and cumulative benefits were similar in patients with and without the baseline involvement of challenging body areas. The authors wrote that the findings imply that patients can achieve similar clear responses and cumulative benefits on ixekizumab no matter if their disease involves challenging body areas at baseline.
Healio also wrote about a JDD study on secukinumab in the treatment of psoriasis in patients with skin of color. The study, “Efficacy and Safety of Secukinumab in the Treatment of Psoriasis in Patients with Skin Phototypes IV to VI,” was conducted by researchers at the Icahn School of Medicine at Mount Sinai and Weill Cornell Medicine in New York. In this single-center, open-label clinical study, 20 adult male and female subjects received secukinumab 300 mg subcutaneously at baseline weekly and through week 4, continuing monthly through week 20. Researchers found 73% of patients achieved PASI90 at week 16, and the dermatology life quality index improved as early as after completion of the loading doses of secukinumab. The authors wrote that the results suggest that secukinumab 300mg subcutaneously is a safe, well-tolerated treatment option for patients with moderate-to-severe plaque psoriasis who have skin of color. In addition, the authors wrote that this study provides an important insight into treating skin of color patients with biologics given the lack of available data as this study includes psoriasis-associated dyspigmentation as a secondary endpoint.
A JDD study on adult acne also made news in Healio. The study, “Challenges in Adult Acne and the Role of Skin Care in Managing the Condition,” was conducted by researchers in the United States and the Netherlands who sought to address skin barrier integrity in adult acne patients and the role of skin care as adjunctive to treatment and maintenance. A panel of eight dermatologists used a modified Delphi method to develop a consensus paper with seven consensus statements. The statements address adult acne’s prevalence in women, lesion location, cosmetically disfiguring sequelae, the role of skin barrier disruption, the role of skincare products in reducing adverse effects, and the importance of repairing and supporting the skin barrier. The authors stressed the importance of improving patient knowledge of acne treatments, including quality cleansers and moisturizers, in order to provide patients with tools for successful treatment.
